This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Company News for Aug 5, 2022
by Zacks Equity Research
Companies in The News Are: COIN, BLK, META, LLY, CI
Eli Lilly (LLY) Misses on Q1 Earnings, Lowers Earnings Guidance
by Zacks Equity Research
Eli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022. The stock falls in pre-market trading.
Jazz's (JAZZ) Q2 Earnings Beat, New Drugs Post Robust Sales
by Zacks Equity Research
JAZZ's Q2 earnings and sales beat expectations on strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. The company affirms its 2022 guidance.
Eli Lilly (LLY) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of -30.56% and 5.91%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program
by Zacks Equity Research
Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.
Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.
United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same. Higher sales of Orenitram and Tyvaso drove the top line in the quarter.
Esperion (ESPR) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.
Drug, Biotech Stocks' Q2 Earnings on Aug 4: LLY, AMGN & More
by Kinjel Shah
Let us look at four large drug and biotech companies, AMGN, VRTX, LLY, NVO, which are gearing up for their earnings release.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Incyte's (INCY) Earnings and Revenues Surpass Estimates in Q2
by Zacks Equity Research
Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Has Alimera Sciences (ALIM) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alimera Sciences (ALIM) and Eli Lilly (LLY) have performed compared to their sector so far this year.
AstraZeneca (AZN) Beats on Q2 Earnings, Ups Sales Growth View
by Zacks Equity Research
AstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.
AbbVie (ABBV) Q2 Earnings Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 1.81% and 0.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $330.80 in the latest trading session, marking a +0.57% move from the prior day.
Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View
by Zacks Equity Research
Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.
Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 11.98% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Innoviva (INVA) Misses Q2 Earnings Estimates
by Zacks Equity Research
Innoviva (INVA) delivered earnings and revenue surprises of -90.91% and 4.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B
by Zacks Equity Research
TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $328.75, marking a +0.56% move from the previous day.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $326.92, marking a +1.52% move from the previous day.
Healthcare ETFs in Focus Ahead of Q2 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FVD